Enteric-coated aspirin is less effective than plain aspirin for preventing cardiovascular events.

  Several studies suggest that enteric-coated aspirin doesn't inhibit platelet aggregations as well as plain aspirin. Researchers speculate that enteric-coated aspirin might not be absorbed as well as plain aspirin in some patients.

  But so far, studies have only looked at measures of platelet function...NOT long-term outcomes. Plus, other research shows that enteric coated aspirin and plain aspirin are equally effective in inhibiting platelet aggregation.

  Tell people there's no proof that enteric-coated aspirin is less effective that plain aspirin for reducing the risk of heart attacks and strokes.